苯丙酮酸钠 | 114-76-1

• 物质功能分类: 化学试剂 - 有机试剂 - 芳香酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 苯丙酮酸钠
• 中文别名: 苯基丙酮酸钠；2-氧代-3-苯基丙酸钠盐；2-氧代-3-苯基丙酸钠
• 英文名称: Sodium phenylpyruvate, powder
• CAS: 114-76-1
• 化学式: C9H8NaO3
• 分子量: 187.15
• InChiKey: UZVNBCKXIIHMIH-UHFFFAOYSA-N

物化性质

• 熔点：
  >300 °C (lit.)
• LogP：
  0.54

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S22,S24/25
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2918300090

制备方法与用途

生物活性

Sodium phenylpyruvate（苯基丙酮酸钠盐）可抑制氨基酸的形成并降低氧气消耗。

文献信息

• Method of treating resistant tumors
  申请人：Wyeth Holdings Corporation

  公开号：US20040121965A1

  公开（公告）日：2004-06-24

  The invention provides a method of treating or inhibiting the growth of or eradicating a tumor in a mammal in need thereof wherein said tumor is resistant to at least one chemotherapeutic agent which method comprises providing to said mammal an effective amount of a compound of Formula II or a pharmaceutically acceptable salt thereof.

  本发明提供了一种治疗或抑制哺乳动物体内对至少一种化疗药物产生耐药性的肿瘤生长或根除肿瘤的方法，该方法包括向该哺乳动物提供有效量的公式II化合物或其药学上可接受的盐。
• Process for producing L-phenylalanine
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP0151488A2

  公开（公告）日：1985-08-14

  A process for producing L-phenylalanine is carried out by (1) culturing a microorganism belonging to the genus Citrobacter, Erwinia, Enterobacter, Klebsiella, Microbacterium, Salmonella, Bacillus, Corynebacterium or Flavobacterium having the ability to convert phenylpyruvic acid into L-phenylalanine in the presence of an amino group donor, in a culture medium containing phenylpyruvic acid and an amino group donor or causing cells of the microorganism or product of treatment thereof to react on phenylpyruvic acid and an amino group donor in an aqueous solution; or by (2) culturing a microorganism belonging to the genus Serratia, Escherichia, Pseudomonas, Enterobacter, Salmonella, Erwinia, Proteus, Citrobacter, Paracoccus, Arthrobacter, Bacillus, Brevibacterium, Corynebacterium, Flavobacterium, Klebsiella, Kluyvera or Micrococcus having the ability to convert phenypyruvic acid into L-phenylalanine in the presence of fumaric acid and ammonium ion or urea, in a culture medium containing phenylpyruvic acid, fumaric acid and ammonium ion or urea or causing cells of said microorganism or product of treatment thereof to react on phenylpyruvic acid, fumaric acid and ammonium ion or urea in an aqueous solution; forming L-phenylalanine in the resultant culture broth or aqueous solution; and recovering L-phenylalanine therefrom.

  一种生产 L-苯丙氨酸的工艺是通过以下方法进行的：(1) 培养一种属于柠檬酸杆菌属、欧文氏菌属、肠杆菌属、克雷伯氏菌属、微杆菌属、沙门氏菌属、芽孢杆菌属、棒状杆菌属或黄杆菌属的微生物，该微生物具有在氨基供体存在下将苯丙酮酸转化为 L-苯丙氨酸的能力、在含有苯丙酮酸和氨基供体的培养基中，或使微生物细胞或其处理产物在水溶液中与苯丙酮酸和氨基供体发生反应；或 (2) 培养属于沙雷氏菌属、埃希氏菌属、假单胞菌属、肠杆菌属、沙门氏菌属、欧文氏菌属、变形杆菌属、柠檬酸杆菌属、副球菌属、节杆菌属、芽孢杆菌属、布氏杆菌属、科里奈杆菌属、黄杆菌属的微生物、具有在富马酸和铵离子或尿素存在下将苯丙酮酸转化为 L-苯丙氨酸能力的棒状杆菌、黄杆菌、克雷伯氏菌、克鲁维拉菌或微球菌、在含有苯丙酮酸、富马酸和铵离子或尿素的培养基中，或使上述微生物的细胞或其处理产物在水溶液中与苯丙酮酸、富马酸和铵离子或尿素发生反应；在产生的培养液或水溶液中形成 L-苯丙氨酸；以及从中回收 L-苯丙氨酸。
• SORBIC ACID AND DERIVATIVES THEREOF TO ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL
  申请人：Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

  公开号：EP3006023A1

  公开（公告）日：2016-04-13

  Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.

  本文提供了治疗神经精神疾病（如精神分裂症、抑郁症、注意力缺陷障碍、轻度认知障碍、痴呆症和双相情感障碍）的方法和组合物。这些方法需要给被诊断为患有神经精神障碍（如精神分裂症、抑郁症、注意力缺陷障碍、轻度认知障碍、痴呆症、双相情感障碍等）或有神经精神障碍风险的患者施用苯甲酸、苯甲酸盐和/或苯甲酸衍生物和/或山梨酸、山梨酸盐和/或山梨酸衍生物，并与神经药剂（如抗精神病药、抗精神病药、抗精神病药、抗精神病药）结合使用、苯甲酸、苯甲酸盐或苯甲酸衍生物和/或山梨酸、山梨酸盐和/或山梨酸衍生物的用量足以提高神经药剂的药效。
• Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
  申请人：Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

  公开号：US10039730B2

  公开（公告）日：2018-08-07

  Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.

  本文提供了治疗神经精神疾病（如精神分裂症、抑郁症、注意力缺陷障碍、轻度认知障碍、痴呆症和双相情感障碍）的方法和组合物。这些方法需要给被诊断为患有神经精神障碍（如精神分裂症、抑郁症、注意力缺陷障碍、轻度认知障碍、痴呆症、双相情感障碍等）或有神经精神障碍风险的患者施用苯甲酸、苯甲酸盐和/或苯甲酸衍生物和/或山梨酸、山梨酸盐和/或山梨酸衍生物，并与神经药剂（如抗精神病药、抗精神病药、抗精神病药、抗精神病药）结合使用、其中苯甲酸、苯甲酸盐或苯甲酸衍生物和/或山梨酸、山梨酸盐和/或山梨酸衍生物的用量足以提高神经药剂的药效。
• TREATMENT OF CNS DISORDERS USING D-AMINO ACID OXIDASE AND D-ASPARTATE OXIDASE ANTAGONISTS
  申请人：GENSET

  公开号：EP1412515A2

  公开（公告）日：2004-04-28